vc-PABC-DM1

• CAT Number: I042317
• CAS Number: 1416792-90-9
• Molecular Formula: C53H75ClN8O13S
• Molecular Weight: 1099.73
• Purity: ≥95%
• Synonyms: [(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] (2S)-2-[3-[[4-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-5-(carbamoylamino)pentanoyl]amino]phenyl]methylsulfanyl]propanoyl-methylamino]propanoate
• IUPAC Name: [(1S,2R,3S,5S,6S,16Z,18Z,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] (2S)-2-[3-[[4-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-5-(carbamoylamino)pentanoyl]amino]phenyl]methylsulfanyl]propanoyl-methylamino]propanoate
• InChI: InChI=1S/C53H75ClN8O13S/c1-29(2)45(55)48(66)59-36(14-12-21-57-50(56)68)47(65)58-35-18-16-33(17-19-35)28-76-22-20-42(63)61(7)32(5)49(67)74-41-26-43(64)62(8)37-24-34(25-38(71-9)44(37)54)23-30(3)13-11-15-40(72-10)53(70)27-39(73-51(69)60-53)31(4)46-52(41,6)75-46/h11,13,15-19,24-25,29,31-32,36,39-41,45-46,70H,12,14,20-23,26-28,55H2,1-10H3,(H,58,65)(H,59,66)(H,60,69)(H3,56,57,68)/b15-11-,30-13-/t31-,32+,36+,39+,40-,41+,45+,46+,52+,53+/m1/s1
• InChIKey: VPFJBLCYMSCFKX-QGIKLSNQSA-N
• SMILES: C[C@@H]1[C@@H]2C[C@]([C@@H](/C=C\C=C(/CC3=CC(=C(C(=C3)OC)Cl)N(C(=O)C[C@@H]([C@]4([C@H]1O4)C)OC(=O)[C@H](C)N(C)C(=O)CCSCC5=CC=C(C=C5)NC(=O)[C@H](CCCNC(=O)N)NC(=O)[C@H](C(C)C)N)C)\C)OC)(NC(=O)O2)O

VC-PABC-DM1（Cat No.:I042317）is an antibody-drug conjugate (ADC) designed for targeted cancer therapy. It consists of a monoclonal antibody (VC) linked to a cytotoxic agent, DM1, through a cleavable linker (PABC). The VC component specifically targets cancer cells expressing a particular antigen, allowing for the selective delivery of DM1. DM1 is a potent microtubule inhibitor, which disrupts cell division and induces apoptosis in targeted cancer cells. The cleavable linker (PABC) ensures that DM1 is released only after internalization, minimizing systemic toxicity while maximizing tumor-specific treatment efficacy.

Reference

[1]. Widdison WC. Novel maytansinoid derivatives with peptide linker and conjugates thereof. WO2012177837A2.